Trial reportImmunity, inflammation and disease2022
A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.
Trial report in Immunity, inflammation and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05611710 (Anakinra for Dengue Patients With Hyperinflammation - a Randomized Double-blind Placebo-controlled Trial), which is not on this map. Cited by 27 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anakinra for Dengue Patients With Hyperinflammation - a Randomized Double-blind Placebo-controlled Trial
Who cites it
27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Clinical efficacy and safety of interleukin-1 blockade in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.Annals of medicine · 2023Pooled it
- Assessment of the available therapeutic approaches for severe COVID-19: a meta-analysis of randomized controlled trials.Scientific reports · 2023Pooled it
- Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis.European journal of medical research · 2023Pooled it
- Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis.Journal of clinical laboratory analysis · 2022Pooled it
- Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.Viruses · 2023Trial
- A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19.Immunity, inflammation and disease · 2022Trial
- Clinical and Psychological Impact of COVID-19 on Maintenance Hemodialysis Patients: Hospitalization Burden, De Novo Anxiolytic Use, and Long-Term Survival.Medicina (Kaunas, Lithuania) · 2026Article
- Weathering the Storm: How Age and Biologics Influence the COVID-19 Cytokine Surge.Pathogens (Basel, Switzerland) · 2025Review
- Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies.Signal transduction and targeted therapy · 2025Review
- IL-1 receptor antagonist: etiological and drug delivery systems overview.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Dynamics of Biomarkers in COVID-19 Patients Treated with Anakinra.Biomedicines · 2024Article
- Immunity and Coagulation in COVID-19.International journal of molecular sciences · 2024Review
- Investigating the impact of Tocilizumab, Sarilumab, and Anakinra on clinical outcomes in COVID-19: A systematic review andInternational journal of cardiology. Heart & vasculature · 2024Review
- Efficacy of COVID-19 Treatments in Intensive Care Unit: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Critical care research and practice · 2024Review
- Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran.Iranian biomedical journal · 2024Article
- An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.International journal of molecular sciences · 2023Review
- Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients.Journal of hematology & oncology · 2023Review
- Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19.European journal of internal medicine · 2023Article
- Assessment of Admission COVID-19 Associated Hyperinflammation Syndrome Score in Critically-Ill COVID-19 Patients.Journal of intensive care medicine · 2023Article
- Evaluation of anakinra in the management of patients with COVID-19 infection: A randomized clinical trial.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHyperinflammatory state has a role in the pathogenesis of COVID-19. Anakinra could reduce inflammation and help to combat the condition. In this study, we aimed to assess the safety and efficacy of anakinra (PerkinRA®) in severe COVID-19.
methodThe study was an open-label, randomized, controlled trial conducted in Imam Hossein Medical Center from May to July 2020. Patients with a confirmed diagnosis of COVID-19 were included in this study. We administered anakinra 100 mg daily intravenously. All patients received COVID-19 pharmacotherapy based on the represented national guideline. The need for invasive mechanical ventilation is considered the primary outcome.
resultsThirty patients were included in this study, and 15 of them received Anakinra. Nineteen patients were male (63.3%), and 11 were female (36.7%). The mean age of patients was 55.77 ± 15.89 years. In the intervention group, the need for invasive mechanical ventilation was significantly reduced compared to the control group (20.0% vs. 66.7%, p = .010). Also, these patients had a significantly lower length of hospital stay (p = .043). No significant higher rate of infection was recorded.
conclusionAnakinra as an immunomodulatory agent has been associated with the reduced need for mechanical ventilation in patients admitted to intensive care units because of severe COVID-19. The medication reduced the hospital length of stay. Furthermore, no increased risk of infection was observed. Further randomized placebo-controlled trials with a larger sample size are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.